Chemical biology and medicinal chemistry of RNA methyltransferases. Issue 8 (12th April 2022)

• Record Type: Journal Article
• Authors: Fischer, Tim R; Meidner, Laurenz; Schwickert, Marvin; Weber, Marlies; Zimmermann, Robert A; Kersten, Christian; Schirmeister, Tanja; Helm, Mark
• Is Part Of: Nucleic acids research. Volume 50:Issue 8(2022)
• Page Start: 4216
• Page End: 4245
• Publication Date: 2022-04-12
• Subjects: Nucleic acids -- Periodicals; Molecular biology -- Periodicals; 572.805
• DOI: 10.1093/nar/gkac224
• Languages: English
• ISSNs: 0305-1048

Abstract

Abstract: RNA methyltransferases (MTases) are ubiquitous enzymes whose hitherto low profile in medicinal chemistry, contrasts with the surging interest in RNA methylation, the arguably most important aspect of the new field of epitranscriptomics. As MTases become validated as drug targets in all major fields of biomedicine, the development of small molecule compounds as tools and inhibitors is picking up considerable momentum, in academia as well as in biotech. Here we discuss the development of small molecules for two related aspects of chemical biology. Firstly, derivates of the ubiquitous cofactor S -adenosyl-l -methionine (SAM) are being developed as bioconjugation tools for targeted transfer of functional groups and labels to increasingly visible targets. Secondly, SAM-derived compounds are being investigated for their ability to act as inhibitors of RNA MTases. Drug development is moving from derivatives of cosubstrates towards higher generation compounds that may address allosteric sites in addition to the catalytic centre. Progress in assay development and screening techniques from medicinal chemistry have led to recent breakthroughs, e.g. in addressing human enzymes targeted for their role in cancer. Spurred by the current pandemic, new inhibitors against coronaviral MTases have emerged at a spectacular rate, including a repurposed drug which is now in clinical trial.